E. R. Zakharochkina

E. R. Zakharochkina

Auto-generated profile, based on publicly available information

E. R. Zakharochkina

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2023 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
GRGarankina R.Y.
Garankina R.Y.
SFSamoshchenkova I. F.
Samoshchenkova I. F.
ZEZaharochkina E.R.
Zaharochkina E.R.
KVKondratova D. V.
Kondratova D. V.
BNBehorashvili N
Behorashvili N
In conditions of budget deficit, the issues of drug provision for patients suffering from life-threatening and chronic progressive rare (orphan) diseases require constant monitoring by regulatory authorities. In this regard, the purpose of the work was to analyze the main aspects of the legal regulation of drug provision for persons with rare (orphan) diseases. The lack of funds in the regions which could fully meet the needs of patients with rare (orphan) diseases in the provision of medicines, served as a weighty argument for the launch of the state federal program for high-costnosologies and the centralization of public procurement of medicines. The key tool for improving drug care was the approval of lists of orphan diseases and the introduction of the federal register of patients eligible for preferential drug provision into the unified information and analytical healthcare system. An important and defining moment of federalization of procurement of medicines was the creation of a federal state institution under the Ministry of Health "Federal Center for Planning and Organization of Drug Provision for Citizens". The main additional mechanism and alternative solution for providing medicines to children under 18 with severe life-threatening and chronic diseases, including rare (orphan) diseases, was the charitable support fund "Circle of Good" created by presidential decree. The financial and organizational approach and the decision of the regulator to federalize the procurement of orphan medicines under the high-cost nosology program makes it possible to increase the equal availability of medicines to persons with rare (orphan) diseases in all subjects of the Russian Federation and to reduce the costs of budget allocations.

2 May 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EZElena Zakharochkina
Elena Zakharochkina
VRVasily Ryazhenov
Vasily Ryazhenov
ESElena Smolyarchuk
Elena Smolyarchuk
DKDmitry Kudlay
Dmitry Kudlay
NBNаna Bekhorashvili
Nаna Bekhorashvili
SSSusanna Sergeevna Sologova
Susanna Sergeevna Sologova
The off-label use of drugs is a common practice worldwide. The legal basis for off-label medical use varies from country to country. Regulatory control of the pharmaceutical market in the off-label preventive and therapeutic practice at the international and national levels has become a breakthrough with the emergence of the coronavirus pandemic. The prospects for off-label use in the context of innovations in the legislation of public health in the Russian Federation are crucial. Professionally significant aspects of the use of medicinal products outside the Summary of Product Characteristics and the off-label use have been introduced by supranational regulatory authorities for the common market of medicinal products of the Eurasian Economic Union. Special attention should be paid to the regulatory control of the use of extemporaneous medicines as part of improving the government regulation of drug compounding in pharmacies. The active development of pharmacy activities in drug compounding within the framework of improving regulatory practice determines the relevance of actual off-label prescriptions and the use of extemporaneous formulations. Aim – to perform a systematic analysis of national, transnational legislative and regulatory documents regulating off-label use of medicinal products, determine the main conceptual components of the current regulatory pool and directions for future development in this area. Systematic analysis of the national legislative and regulatory pool of documents and the regulatory framework of the common market of medicinal products of the Eurasian Economic Union on the regulation of various aspects of the off-label use of medicinal products. Study of the components and identification of the main trends in the regulatory practice of prescriptions outside the Summary of Product Characteristics and the off-label use. An analytical search was carried out in the reference legal systems "ConsultantPlus" and "Garant" on the official websites of the Ministry of Health of Russia, the Eurasian Economic Union, the RusMed information resource of the National Library resource of Russia in medicine and pharmacy "Central Scientific Medical Library" was used. A logical generalization of the results on the current state of the legal framework and the development of conceptual proposals on the key directions of the prospective development of regulation, control, and supervisory activities of the pharmaceutical off-label use of medicinal products was made.

29 June 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
VRV. V. Ryazhenov
V. V. Ryazhenov
EME. A. Maksimkina
E. A. Maksimkina
VFV. S. Fisenko
V. S. Fisenko
AAA. V. Alekhin
A. V. Alekhin
VTVadim V. Tarasov
Vadim V. Tarasov
RGR. Yu. Garankina
R. Yu. Garankina
The aim of the work was to analyze the current regulatory legal framework governing the manufacture of drugs in pharmacies, and a comprehensive review of the current state of their manufacture; a disclosure of problems and search for the ways to improve the sphere of circulation of extemporaneously compounded medicines (ECMs).Materials and methods. The national legislation of the Russian Federation and the regulatory framework of the medicines common market of the Eurasian Economic Union in the field of an extemporaneous drugs circulation formed a regulatory base of the work. To collect and analyze the information data, the materials presented on the official websites of the Ministry of Health of Russia, the Ministry of Industry and Trade of Russia have been used. The results of the scientific publications for the previous 10 years (2014–2024) have also been analyzed.Results. The article deals with the current state issues of the drug products manufactured in pharmacies, in the sphere of circulation. The analysis of the legislative base on ECMs has been carried out, the problems of the normative legal regulation of the pharmacy drugs manufacturing have been identified. The introduction of new relevant concepts into Federal Law No. 61-FZ “On Circulation of Medicines” — “extemporaneous drug products”, “extemporaneous manufacturing”, “extemporaneous production” — has been proposed. The authors’ definition of the “pharmaceutical sovereignty” concept was given in the course of the study. Based on the results of the study, the possibilities and ways of improving the mechanisms of the state regulation of the drugs extemporaneous manufacturing in the current political and economic conditions have been identified.Conclusion. The operational management and systematization of the regulatory legal framework of the ECMs circulation sphere based on the regulatory science is the most important factor in increasing the affordable, effective, personalized pharmaceutical care. An important element of the mobilization model of the economy is strengthening of the state regulation, development of the domestic production capacities and technologies, including taking into account extemporaneous manufacturing of drugs and small-scale production.

23 July 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
RGR. Yu. Garankina
R. Yu. Garankina
VRV. V. Ryazhenov
V. V. Ryazhenov
EME. A. Maksimkina
E. A. Maksimkina
VFV. S. Fisenko
V. S. Fisenko
AAA. V. Alekhin
A. V. Alekhin
EZE. R. Zakharochkina
E. R. Zakharochkina
To date, pharmaceutical activities in the manufacture of medicines in a pharmacy, intra-pharmacy packaging of registered medicines in Russia and the countries of the Eurasian Economic Union (EAEU), is one of the priorities of regulatory authorities in order to improve drug supply.The aim. To study the current state of legal regulation of the circulation of medicines “in bulk” and the possibility of their packaging in a pharmacy.Materials and methods. To solve the tasks set, the methodology of system analysis in the field of drug provision, content analysis of documents regulating the sphere of circulation of drugs was used. The regulatory framework of the study was the legislative and by-laws regulating the sphere of circulation of medicines of the Russian Federation and the common market of the EAEU. The search for regulatory legal acts was carried out in the Directory of the legal system “ConsultantPlus”. In the course of the research, a set of scientific methods was used such a systematic, logical, structural and comparative.Results. The article consider the issues of legal regulation of the circulation of medicines “in bulk” in the pharmaceutical market. The current state of the legislative and regulatory framework has been studied and the problems of legal regulation of packaging of medicicnes “in bulk” in pharmacies have been identified. The article also focuses on the general problem of compliance with modern packaging requirements for medicines compounded in pharmacy. The possibility of introducing a new concept of “Pharmacy packaging” into Federal Law No. 61-FZ dated April 12, 2010 “On the circulation of medicines” is considered. The approaches developed in world practice to the regulation of issues related to the packaging of drugs “in bulk” in pharmacy are considered. Based on the results of the study, the possibilities have been identified and ways to improve the mechanisms of state regulation have been proposed.Conclusion. Packaging of medicines “in bulk” will increase the effectiveness of individual drug therapy, optimize and reduce the cost of circulation of budget funds, pharmacies and citizens.

2 August 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
VRV. V. Ryazhenov
V. V. Ryazhenov
EME. A. Maksimkina
E. A. Maksimkina
VFV. S. Fisenko
V. S. Fisenko
AAA. V. Alekhin
A. V. Alekhin
VTVadim V. Tarasov
Vadim V. Tarasov
RGR. Yu. Garankina
R. Yu. Garankina
Referred to by: Ryazhenov V.V., Maksimkina E.A., Fisenko V.S., Alekhin A.V., Tarasov V.V., Raisyan M.G., Zakharochkina E.R., Chizhov K.A., Garankina R.Yu. Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia. Pharmacy & Pharmacology. 2024;12(5):324-337. https://doi.org/10.19163/2307-9266-2024-12-5-324-337 We hereby inform readers that in the final version of the article changes were made in Russian and English.In the published article " Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia", the authors found an error: accidentally, due to a technical error on part and without any malicious intent, еhe regulatory document was incorrectly specified in table 1 (p.330):Resolution of the Government of the Russian Federation No. 546 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022.The authors regret that, due to an oversight, the cited regulatory document was incorrectly numbered (No. 546) in the originally published version of this article.Correct version:Resolution of the Government of the Russian Federation No. 547 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022. The error occurred due to the fault of the entire team of authors, but does not change the essence of the data presented in the article, does not violate their perception by readers or interpretation.The authors would like to apologize for any inconvenience. The authors declare no conflict of interest.The original article has been updated in online-version: https://www.pharmpharm.ru/jour/article/view/1664